SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN)
BTRN 35.45+0.1%4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (23)7/15/1998 1:28:00 AM
From: Larry Liebman  Read Replies (1) of 1475
 
O.K. Richard...What am I missing? There are 8.5 million shares out. With BTRN at $3 you're talking about a market cap of $25.5 million. As of 3/31/98 cash and equivalents were at $27 million.
In the investor packet they discuss such items as: (a) the Novartis xenotransplantation agreement with an implied value of $36 million (b) the breakout of MEDI-507 into autoimmune diseases like psoriasis- and the partnership with MedImmune, and (c) a 30% equity stake in an Australian firm known as Stem Cell Sciences, which has entered into an agreeement with Genentech. This ignores the primary work of BTRN in organ rejection, with products in clinical trials. I have to agree with your assessment, BTRN looks compelling at these levels.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News